Difference between revisions of "Team:UCopenhagen/Description"

 
(76 intermediate revisions by 5 users not shown)
Line 2: Line 2:
 
{{UCopenhagen}}
 
{{UCopenhagen}}
 
{{Template:UCopenhagen/Header3}}
 
{{Template:UCopenhagen/Header3}}
 
+
{{Template:UCopenhagen/Footnotes}}
  
 
<html>
 
<html>
Line 9: Line 9:
  
 
.page-wrapper{
 
.page-wrapper{
  margin: auto;
+
  margin-bottom: -45%;
  width: 65%;
+
  margin-top: -5%;
  position: center;
+
max-width: 100%;
 +
background-image: url("https://static.igem.org/mediawiki/2020/a/a3/T--UCopenhagen--watercolor_bg_smaller.png");
 +
background-repeat: repeat-y;
 +
background-size: 100%;
 +
background-color: #fcecdf;
 +
padding-top:5%;
 +
padding-bottom: 35%;
 +
padding-left: 15%;
 +
padding-right: 15%;
 +
text-align: justify;
 +
}
 +
 
 +
 
 +
 
 +
.page-wrapper h2{
 +
margin-top: 5%;
 +
        margin-bottom: 3.5%;
 +
        font-family: Montserrat;
 +
        font-size: 28px;
 +
      line-height: 1.2;}
 +
 
 +
.page-wrapper h3{
 +
margin-top: 5%;
 +
        margin-bottom: 3.5%;
 +
        font-family: Montserrat;
 +
        font-size: 24px;
 +
      line-height: 1.2;}
 +
 
 +
.page-wrapper h4{
 +
margin-top: 5%;
 +
        margin-bottom: 3.5%;
 +
        font-family: Montserrat;
 +
        font-size: 20px;
 +
      line-height: 1.2;}
 +
 
 +
 
 +
 
 +
#top-image img {
 +
width: 100%;
 +
height: 94vh;
 +
margin-top: -3em;
 +
position: relative;
 +
-o-object-fit: cover;
 +
object-fit: cover;
 +
 
 +
}
 +
 
 +
#title-box{
 +
z-index: 1;
 +
margin-top: 20px;
 +
margin-left: 5%;
 +
border-right: solid;
 +
border-bottom: solid;
 +
border-color: #FF5782;
 +
text-align: right;
 +
border-radius: 0px 0px 20px 0px;
 +
padding-right: 20px
 +
  position: relative;
 
   
 
   
 
}
 
}
.container-img{
+
#title-box-corner{
  }
+
  position: relative;
.text{
+
bottom:-20px;
 
+
right:10px;
 +
 
}
 
}
  
#top-image img {
+
#title-box h1{
  max-width: 100%;
+
  font-size: 3em;
  height: auto;
+
  line-height: 1.0em;
z-index: -1;
+
   
  margin-top: -3%;
+
position: relative
+
 
}
 
}
  
  
</style>
 
</head>
 
  
<body>
+
.left-border-box{
 +
border-left: solid;
 +
border-bottom: solid;
 +
border-top: solid;
 +
border-radius: 20px 0px 0px 20px;
 +
border-color: #FF5782;
 +
margin-right: 5em;
 +
margin-top: -0.25em;
 +
padding-left: 5em;
 +
 +
}
  
<div class="container-img">
+
.right-border-box{
  <div id="top-image">
+
border-right: solid;
  <img src="https://static.igem.org/mediawiki/2020/f/f9/T--UCopenhagen--Temporary_Group_Photo_PlaceHolder.jpg">
+
border-bottom: solid;
  </div>
+
border-top: solid;
</div>
+
border-radius: 0px 20px 20px 0px;
<div class="page-wrapper">
+
border-color: #FF5782;
<h1>Project description</h1>
+
margin-left: 5em;
 +
margin-top: -0.25em;
 +
padding-right: 5em;
 +
}
  
<p>
 
<h4>Defining the problem</h4>
 
  
Generally, people who suffer from CID’s need to monitor their conditions closely. This may include regular hospital visits to measure levels of inflammation and monitor the disease progression. These visits are not only time consuming but exhausting to the patients mentally. Vast research have been conducted, linking hospitalization and depression in patients (REF). Even short visits to your hospital for routine blood samples or check-ups can have a negative impact on mental well-being. Not only does the visits remind patients of the fact that they are ‘sick’, but the time spent on transport and testing is a live-long burden to the individual.
+
.box-flex-divider{
Monitoring the disease is crucial for treatment, yet still 1 out of 3 patients with CID’s receives non-effective treatment (REF). CID’s can behave extremely different from patient to patient, so individual adjustment of treatments is needed, however data on treatment variations are not available for all patient groups?? Thus continuous monitoring of inflammation levels specific for the individual can provide immense benefit for the patient in periods of treatment adjustments or disease relapse.
+
display:flex;
Current methods for disease tracking are almost exclusively invasive and includes blood-sampling and on occasion more comprehensive procedures such as endoscopies. Invasive methods of testing not only expensive and requiring well trained personal, but they are also unpleasant and could in worst case lead to complications for the patients. In addition they do not allow the patient to self-monitor, hence the need for extensive hospital visits.
+
flex-direction: row;
Conclusively, suffering from a chronic inflammatory disease can be extremely exhausting both physically and mentally. Although much research is being conducted in regards to the treatment of all types of inflammatory diseases, not many monitoring devices exists to make it easier for the individual living with a CID. In order to improve the quality of life for patients worldwide, we have created CIDosis.
+
 +
}
 +
.box-flex-divider img{
 +
max-width: 75%;
 +
}
  
</p>
+
.box-flex-big{
 +
flex: 2;
 +
padding: 1em;
 +
 +
}
  
<p>
 
<h4>Our Solution</h4>
 
With CIDosis, we provide a non-invasive device, allowing CID patients to monitor their own inflammation status. CIDosis aims to improve the quality of life for patients who suffer from chronic inflammatory diseases by providing a patch that will detect levels of inflammatory markers in their sweat. This patch can be placed under the armpit of the patient where it will be continuously collecting sweat during the day, resulting in a color output translating the inflammatory status. 
 
Our self-monitoring patch, CIDosis, is an easy-to-use, non-invasive device suitable for home use, and will decrease the need for frequent hospital visits,
 
thereby making life easier for the patients. It allows for transparency for the patient regarding their disease progression and is a tool that can help them discover the best self-management strategy for their disease. Not only can it alleviate the burden of hospital visits, but it can provide valuable information on the therapeutic efficacy of certain drugs, allowing for faster treatment adjustments and continuous dosage regulations as the disease progresses. 
 
We envision the use of this patch as a future self-monitoring system for patients suffering from inflammatory diseases worldwide. With the CIDosis patch they have access to a cheap, non-invasive method to measure their daily inflammation in an easy way and track their condition. The utility of such a device is extensive and can alleviate the struggles of many patient groups from Crohn’s disease to Arthritis.
 
  
 +
.box-flex-small-first{
 +
flex: 1;
 +
justify-content: center;
 +
padding: 1em;
 +
display: flex;
 +
align-items: center;
 +
margin-left: -31%;
  
</p>
+
 +
}
  
<p>
 
<h4>Scientific approach</h4>
 
We are engineering the yeast Saccharomyces cerevisiae to sense presence of inflammation biomarkers (interleukins/cytokines) in human sweat. The yeast is located inside a sweat patch specifically designed for this purpose. Our SPY (Sweat Patch with Yeast) device is placed on the skin, where it continually collects sweat from the patient. The yeast expresses a colored pigment to reflect the level of a certain interleukin of choice. The vision is a modular design, allowing for easy swap of the interleukin receptor in the yeast, so the patch can be tailored to the need of the individual patient group. The yeast is powered by designed receptors that boast very high sensitivity and selectivity, coupled with an efficient pheromone pathway for signal amplification. The SPY can be photographed with a specialized app to analyze the exact level of coloration regardless of light conditions. 
 
</p><p>
 
The detailed step of the scientific development includes: 
 
</p><p>
 
<b>Interleukin receptor modification</b>
 
Human interleukin receptors are cloned into yeast, via a fusion between the extracellular receptor domain and an endogenous yeast transmembrane protein. Successful ligand-receptor binding is tested via a common split-ubiquitin signal assay.
 
</p><p>
 
<b>Hijacking the yeast pheromone pathway </b>
 
The interleukin signal is amplified for more precise measurement by hijacking the signal amplification steps of the pheromone pathway in yeast. Endogenous G-alpha proteins are modified to induce the pathway upon ligand-receptor binding.
 
</p><p>
 
<b>Signal transduction via color expression </b>
 
The signal pathway will, post amplification, induce the transcription of a colorful pigment that will then be expressed in the yeast cell, resulting in a clear, visual color change of the yeast colony.
 
  
 +
.box-flex-small-last{
 +
flex: 1;
 +
justify-content: center;
 +
padding: 1em;
 +
display: flex;
 +
align-items: center;
 +
margin-right: -33%;
 +
 +
 +
}
  
</p>
 
  
</div>
+
.box-flex-text{
 +
display:flex;
 +
flex-direction: column;
 +
text-align: justify;
 +
justify-text: inter-word;
  
<div class="column full_size judges-will-not-evaluate">
+
}
<h3>★  ALERT! </h3>
+
<p>This page is used by the judges to evaluate your team for the <a href="https://2020.igem.org/Judging/Medals">medal criterion</a> or <a href="https://2020.igem.org/Judging/Awards"> award listed below</a>. </p>
+
<p> Delete this box in order to be evaluated for this medal criterion and/or award. See more information at <a href="https://2020.igem.org/Judging/Pages_for_Awards"> Instructions for Pages for awards</a>.</p>
+
</div>
+
  
 +
.box-flex-text h5{
 +
font-family: Bavro;
 +
        font-size: 35px;
 +
        color: #F3557E;
 +
        line-height: 1;
 +
text-align: center;
 +
margin-top: 5%;
 +
}
  
<div class="clear"></div>
 
  
<div class="column full_size">
+
.box-flex-text div{
<h1>Project Description </h1>
+
padding: 1em;
<h3>Bronze Medal Criterion #3</h3>
+
}
  
<p>Describe how and why you chose your iGEM project.
+
.box-flex-text img{max-width: 100%;}
<br><br>
+
Please see the <a href="https://2020.igem.org/Judging/Medals">2020 Medals Page</a> for more information.
+
</p>
+
</div>
+
  
 +
.lastbox{
 +
border-right: solid;
 +
border-top: solid;
 +
border-radius: 0px 20px 0px 0px;
 +
border-color: #FF5782;
 +
margin-left: 2em;
 +
margin-top: -0.25em;
 +
padding-right: 2em;
 +
}
  
 +
@media only screen and (max-width: 800px) {
  
<div class="column two_thirds_size">
+
.box-flex-divider img{
<h3>What should this page contain?</h3>
+
max-width: 60%;}
<ul>
+
<li> A clear and concise description of your project.</li>
+
<li>A detailed explanation of why your team chose to work on this particular project.</li>
+
<li>References and sources to document your research.</li>
+
<li>Use illustrations and other visual resources to explain your project.</li>
+
</ul>
+
</div>
+
  
<div class="column third_size" >
+
.page-wrapper{
<div class="highlight decoration_A_full">
+
margin: auto;
<h3>Inspiration</h3>
+
width: 95%;
<p>See how other teams have described and presented their projects: </p>
+
position: relative;
 +
font-family: Montserrat;}
  
<ul>
+
.box-flex-divider{
<li><a href="https://2016.igem.org/Team:Imperial_College/Description">2016 Imperial College</a></li>
+
display:flex;
<li><a href="https://2016.igem.org/Team:Wageningen_UR/Description">2016 Wageningen UR</a></li>
+
flex-direction: column;
<li><a href="https://2014.igem.org/Team:UC_Davis/Project_Overview"> 2014 UC Davis</a></li>
+
}
<li><a href="https://2014.igem.org/Team:SYSU-Software/Overview">2014 SYSU Software</a></li>
+
 
</ul>
+
.box-flex-big{
</div>
+
padding: 0.1em;
 +
}
 +
 
 +
.box-flex-small-first{
 +
flex: 1;
 +
padding: 0.1em;
 +
display: flex;
 +
align-items: center;
 +
justify-content: center;
 +
margin-left: 0;
 +
}
 +
 
 +
.box-flex-small-last{
 +
flex: 3;
 +
padding: 0.1em;
 +
display: flex;
 +
align-items: center;
 +
justify-content: center;
 +
margin-right: 0;}
 +
 
 +
 +
.box-flex-text{
 +
display:flex;
 +
flex-direction: column;
 +
font-size: 16px;
 +
line-height: 1.4;
 +
}
 +
 
 +
.left-border-box{
 +
border-left: solid;
 +
border-bottom: solid;
 +
border-top: solid;
 +
border-radius: 20px 0px 0px 20px;
 +
border-color: #FF5782;
 +
margin-right: 2em;
 +
margin-top: -0.25em;
 +
padding-left: 2em;
 +
 +
}
 +
 
 +
.right-border-box{
 +
border-right: solid;
 +
border-bottom: solid;
 +
border-top: solid;
 +
border-radius: 0px 20px 20px 0px;
 +
border-color: #FF5782;
 +
margin-left: 2em;
 +
margin-top: -0.25em;
 +
padding-right: 2em;
 +
}
 +
 
 +
 
 +
</style>
 +
</head>
 +
 
 +
<body>
 +
 
 +
 
 +
  <div id="top-image">
 +
  <img src="https://static.igem.org/mediawiki/2020/0/0e/T--UCopenhagen--description-cover.png">
 +
  </div>
 +
 
 +
<div class="page-wrapper">
 +
<div id="title-box">
 +
  <div id="title-box-corner">
 +
 
 +
    <h1 style="font-family: Bavro; font-size: 45px; color: #0c2f4b"> Project description <br> & inspiration </h1>
 +
    </div>
 +
</div>
 +
 
 +
<div class="left-border-box">
 +
    <div class="box-flex-divider">
 +
        <div class="box-flex-small-first">
 +
       
 +
        <img style="background-color: #fcecdf; padding:2%; border-radius: 50px;" src="https://static.igem.org/mediawiki/2020/9/93/T--UCopenhagen--problem_desc.png"> </div>
 +
       
 +
        <div class="box-flex-big">
 +
              <div class="box-flex-text">
 +
                     
 +
          <h5>Defining the problem</h5>
 +
       
 +
                   
 +
                    <div style="font-family: Avenir, Arial; font-size:16px;">
 +
             
 +
<b>Chronic inflammatory diseases</b> (CIDs), such as juvenile and adult rheumatoid arthritis, asthma and inflammatory bowel disease, are life-long, debilitating illnesses, where patients suffer from <b> chronic pain,</b> fatigue, swelling and fever. Due to the complicated disease profiles, treatments for CIDs do not always work and there is usually a <b> long search</b> process for the <b>right treatment </b> <a href="#WHO" aria-describedby="footnote-label" id="WHO-ref"> </a> <a href="#CID" aria-describedby="footnote-label" id="CID-ref"> </a> <a href="#furman" aria-describedby="footnote-label" id="furman-ref"> </a>.
 +
 
 +
 +
                  </div>
 +
                    <div style="font-family: Avenir, Arial; font-size:16px;">
 +
Generally, people who suffer from CIDs need to monitor their conditions closely. This may include frequent and <b>regular hospital visits </b> to measure levels of inflammation and monitor disease progression. These visits are not only time-consuming but also <b> mentally exhausting </b> to the patients. Not only do the visits remind patients of their illness, but the time spent on transport and testing is a life-long burden on the individual. Current methods for disease tracking are almost exclusively <b> invasive </b> and include blood sampling and, occasionally, more comprehensive procedures such as endoscopy. Invasive methods of testing are not only expensive and unpleasant but also require <b>highly trained personnel</b> and do not allow the patient to self-monitor, requiring regular hospital visits. Ideally, patients should be tested more often to provide a clear picture of the disease and catch inflammatory changes when they happen. However, the invasive nature of current methods renders testing on a weekly basis <b>impractical and expensive</b>. 
 +
                    </div>
 +
          <div style="font-family: Avenir, Arial; font-size:16px;">
 +
 
 +
Conclusively, suffering from a chronic inflammatory disease can be extremely exhausting both physically and mentally. Although wide research is being conducted in regards to the treatment of all types of inflammatory diseases, not many monitoring devices exist to make life easier for the individual living with a CID and provide <b>continuous tracking</b> of their condition. In order to improve the quality of life for patients worldwide, we have created CIDosis.</div>
 +
 
 +
                  </div>
 +
            </div>
 +
        </div>
 +
  </div>
 +
 
 +
<div class="right-border-box">
 +
    <div class="box-flex-divider">
 +
        <div class="box-flex-big">
 +
          <div class="box-flex-text">
 +
           
 +
            <h5>Our Solution</h5>
 +
         
 +
            <div style="font-family: Avenir, Arial; font-size:16px;"> With CIDosis, we aim to improve the quality of life of patients, by providing a <b> non-invasive device </b> that will allow CID patients to <b> monitor</b> their own inflammation status from the comfort of their home. Our device consists of a patch that detects the levels of inflammatory markers in the <b>sweat</b>. This patch will be placed on the patient’s skin, where it will continuously collect sweat during the day, resulting in a <b> color output</b> reflecting the inflammatory status. The intensity of the color will correlate with the inflammation level. By employing a <d>dedicated app</d>, the patient will be able to track the color intensity using the camera of their mobile phone.  </div>
 +
          <div style="font-family: Avenir, Arial; font-size:16px;">
 +
Our <b> self-monitoring patch </b>, CIDosis, is an <b> easy-to-use</b>, non-invasive device, suitable for home use, and will decrease the need for frequent hospital visits, thereby making life easier for the patients. It allows for transparency for the patient regarding their <b>disease progression</b> and is a tool that can help them discover the best self-management strategy for their disease. Not only can it alleviate the burden of hospital visits, but it can provide valuable information on the therapeutic efficacy of certain drugs, allowing for <b> faster treatment adjustments </b> and continuous dosage regulations as the disease progresses. 
 +
</div>
 +
        <div style="font-family: Avenir, Arial; font-size:16px;"> We envision the use of this patch as a future self-monitoring system for patients suffering from chronic inflammatory diseases worldwide. With the CIDosis patch they have access to a cheap, non-invasive method to measure their daily inflammation and track their condition in an easy way. The utility of such a device is extensive and can alleviate the struggles of many patient groups from Crohn’s disease to Rheumatoid Arthritis. </div>
 +
          </div>
 +
        </div>
 +
        <div class="box-flex-small-last">
 +
          <img style="border-radius: 25px; background-color: #fcecdf; padding:3%; width: 120%;" src="https://static.igem.org/mediawiki/2020/f/fd/T--UCopenhagen--complete_patch.png">
 +
        </div>
 +
    </div>          
 
</div>
 
</div>
  
  
  
 +
<div class="left-border-box">
  
<div class="column two_thirds_size" >
+
<div class="box-flex-divider">
<h3>Advice on writing your Project Description</h3>
+
        <div class="box-flex-big">
 +
              <div class="box-flex-text">
 +
                     
 +
                  <h5>Scientific approach</h5>
 +
                   
 +
                    <div>
 +
                <img src="https://static.igem.org/mediawiki/2020/4/4c/T--UCopenhagen--rendered_2.png">
 +
              </div>
 +
<div style="font-size: 13px;"> Figure 1: Visual representation of the usage of the CIDosis patch and the engineering and scientific approach. 1: The patch collecting sweat from the skin. 2: The layers in the patch. 3: The scientific receptor engineering. 4: The patch after it has changed color. 5: The image-analyzing app. </div>
 +
                    <div style="font-family: Avenir, Arial; font-size:16px;">
 +
Our project is founded on previous research showing the <b> presence of interleukins IL-1β, IL-6 or IL-10 (ILs) in sweat </b> <a href="#katch" aria-describedby="footnote-label" id="katch-ref"> </a> <a href="#hladek" aria-describedby="footnote-label" id="hladek-ref"> </a>, and the correlation with their respective levels in blood <a href="#marq" aria-describedby="footnote-label" id="marq-ref"> </a>. The CIDosis patch implementation is based on an engineered <b><i>Saccharomyces cerevisiae </i></b> (Baker’s yeast) biosensor capable of detecting the inflammation markers IL-1, 6 and 10. Incorporation of modified <b>Human Interleukin receptors</b> in yeast are backed by previous research showing successful expression of soluble IL receptors in yeast <a href="#voll" aria-describedby="footnote-label" id="voll-ref"> </a>. The activation of the biosensor leads to the expression of a pigment biosynthesis gene and further to the accumulation of a colored compound. The biosensor will be located inside a patch specifically designed to sit on the skin and continuously collect sweat from the user for up to 24 hours. Once interleukins from the sweat reach the patch, our yeast receptors will sense their presence, and produce the aforementioned colored pigment corresponding to the level of the IL in question.
 +
</br></br>
 +
The biosensor design (Fig. 1) relies on the dimerization of modified human IL receptors on the yeast plasma membrane upon activation by their respective ligands. The modified receptors contain a synthetic transcription factor  bound on their intracellular side that can be released upon dimerization of the receptors. Specifically, dimerization of the receptors leads to the co-localization of two halves of a <b>split-actuator protein,</b> which, when reunited, leads to cleavage of the protein resulting in the release of the transcription factor. The synthetic transcription factor, in turn, binds a specific synthetic promoter and finally activates the expression of the <b>colorimetric reporter gene </b>.
 +
</br></br>
 +
Our vision is a <b> modular design </b>, allowing for easy swap of the interleukin receptor in the yeast, so the patch can be tailored to the need of the individual patient group. The yeast is powered by designed receptors that boast very high sensitivity and selectivity, coupled with an efficient pheromone pathway for signal amplification. The patch can be photographed with a specialized app to analyze the exact level of coloration regardless of light conditions. 
 +
                  </div>
 +
           
  
<p>
+
                  </div>
We encourage you to put up a lot of information and content on your wiki, but we also encourage you to include summaries as much as possible. If you think of the sections in your project description as the sections in a publication, you should try to be concise, accurate, and unambiguous in your achievements. Your Project Description should include more information than your project abstract.
+
         
</p>
+
            </div>
  
 +
        </div>
 +
 +
  </div>
 +
 +
<div class="lastbox">
 +
</br></br></br></br>
 
</div>
 
</div>
  
<div class="column third_size">
+
</div>
<h3>References</h3>
+
<p>iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you thought about your project and what works inspired you.</p>
+
  
 +
<div>
 +
</br></br></br></br>
 
</div>
 
</div>
  
 +
<!-- inserting our footnotes -->
 +
<div class="ref_cont" style="margin-top:2%;">
 +
    <div class="refs">
 +
      <ol>
 +
        <li id="WHO">JoAnne Epping-Jordan, Robert Beaglehole, Catherine Le Galès-Camus, et al.  Preventing chronic diseases: a vital investment. 2005. WHO global report.
 +
<a href="#WHO-ref" aria-label="Back to content">↩</a></li>
 +
        <li id="CID">Pahwa R, Goyal A, Bansal P, et al. Chronic Inflammation. 2020 Jul 4. Treasure Island (FL): StatPearls [Internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493173/<a href="#CID-ref" aria-label="Back to content">↩</a></li>
 +
<li id="furman">Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-1832. doi:10.1038/s41591-019-0675-0<a href="#furman-ref" aria-label="Back to content">↩</a></li>
 +
<li id="katch">Katchman BA, Zhu M, Blain Christen J, Anderson KS. Eccrine Sweat as a Biofluid for Profiling Immune Biomarkers. Proteomics Clin Appl. 2018;12(6):e1800010. doi:10.1002/prca.201800010<a href="#katch-ref" aria-label="Back to content">↩</a></li>
 +
<li id="marq">Marques-Deak A, Cizza G, Eskandari F, et al. Measurement of cytokines in sweat patches and plasma in healthy women: validation in a controlled study. J Immunol Methods. 2006;315(1-2):99-109. doi:10.1016/j.jim.2006.07.011<a href="#marq-ref" aria-label="Back to content">↩</a></li>
 +
<li id="hladek">Hladek MD, Szanton SL, Cho YE, et al. Using sweat to measure cytokines in older adults compared to younger adults: A pilot study. J Immunol Methods. 2018;454:1-5. doi:10.1016/j.jim.2017.11.003 <a href="#hladek-ref" aria-label="Back to content">↩</a></li>
 +
<li id="voll">Vollmer P, Peters M, Ehlers M, et al. Yeast expression of the cytokine receptor domain of the soluble interleukin-6 receptor. J Immunol Methods. 1996;199(1):47-54. doi:10.1016/s0022-1759(96)00163-9 <a href="#voll-ref" aria-label="Back to content">↩</a></li>
  
 +
      </ol>
 +
    </div>
 +
</div>
 +
 +
 +
 +
 +
 +
</div>
  
  
Line 152: Line 390:
 
</html>
 
</html>
  
{{Template:UCopenhagen/Footer_2}}
+
{{Template:UCopenhagen/Footer_Bubbly_sponsors}}

Latest revision as of 01:19, 27 October 2020

Project description
& inspiration

Defining the problem
Chronic inflammatory diseases (CIDs), such as juvenile and adult rheumatoid arthritis, asthma and inflammatory bowel disease, are life-long, debilitating illnesses, where patients suffer from chronic pain, fatigue, swelling and fever. Due to the complicated disease profiles, treatments for CIDs do not always work and there is usually a long search process for the right treatment .
Generally, people who suffer from CIDs need to monitor their conditions closely. This may include frequent and regular hospital visits to measure levels of inflammation and monitor disease progression. These visits are not only time-consuming but also mentally exhausting to the patients. Not only do the visits remind patients of their illness, but the time spent on transport and testing is a life-long burden on the individual. Current methods for disease tracking are almost exclusively invasive and include blood sampling and, occasionally, more comprehensive procedures such as endoscopy. Invasive methods of testing are not only expensive and unpleasant but also require highly trained personnel and do not allow the patient to self-monitor, requiring regular hospital visits. Ideally, patients should be tested more often to provide a clear picture of the disease and catch inflammatory changes when they happen. However, the invasive nature of current methods renders testing on a weekly basis impractical and expensive.
Conclusively, suffering from a chronic inflammatory disease can be extremely exhausting both physically and mentally. Although wide research is being conducted in regards to the treatment of all types of inflammatory diseases, not many monitoring devices exist to make life easier for the individual living with a CID and provide continuous tracking of their condition. In order to improve the quality of life for patients worldwide, we have created CIDosis.
Our Solution
With CIDosis, we aim to improve the quality of life of patients, by providing a non-invasive device that will allow CID patients to monitor their own inflammation status from the comfort of their home. Our device consists of a patch that detects the levels of inflammatory markers in the sweat. This patch will be placed on the patient’s skin, where it will continuously collect sweat during the day, resulting in a color output reflecting the inflammatory status. The intensity of the color will correlate with the inflammation level. By employing a dedicated app, the patient will be able to track the color intensity using the camera of their mobile phone.
Our self-monitoring patch , CIDosis, is an easy-to-use, non-invasive device, suitable for home use, and will decrease the need for frequent hospital visits, thereby making life easier for the patients. It allows for transparency for the patient regarding their disease progression and is a tool that can help them discover the best self-management strategy for their disease. Not only can it alleviate the burden of hospital visits, but it can provide valuable information on the therapeutic efficacy of certain drugs, allowing for faster treatment adjustments and continuous dosage regulations as the disease progresses.
We envision the use of this patch as a future self-monitoring system for patients suffering from chronic inflammatory diseases worldwide. With the CIDosis patch they have access to a cheap, non-invasive method to measure their daily inflammation and track their condition in an easy way. The utility of such a device is extensive and can alleviate the struggles of many patient groups from Crohn’s disease to Rheumatoid Arthritis.
Scientific approach
Figure 1: Visual representation of the usage of the CIDosis patch and the engineering and scientific approach. 1: The patch collecting sweat from the skin. 2: The layers in the patch. 3: The scientific receptor engineering. 4: The patch after it has changed color. 5: The image-analyzing app.
Our project is founded on previous research showing the presence of interleukins IL-1β, IL-6 or IL-10 (ILs) in sweat , and the correlation with their respective levels in blood . The CIDosis patch implementation is based on an engineered Saccharomyces cerevisiae (Baker’s yeast) biosensor capable of detecting the inflammation markers IL-1, 6 and 10. Incorporation of modified Human Interleukin receptors in yeast are backed by previous research showing successful expression of soluble IL receptors in yeast . The activation of the biosensor leads to the expression of a pigment biosynthesis gene and further to the accumulation of a colored compound. The biosensor will be located inside a patch specifically designed to sit on the skin and continuously collect sweat from the user for up to 24 hours. Once interleukins from the sweat reach the patch, our yeast receptors will sense their presence, and produce the aforementioned colored pigment corresponding to the level of the IL in question.

The biosensor design (Fig. 1) relies on the dimerization of modified human IL receptors on the yeast plasma membrane upon activation by their respective ligands. The modified receptors contain a synthetic transcription factor bound on their intracellular side that can be released upon dimerization of the receptors. Specifically, dimerization of the receptors leads to the co-localization of two halves of a split-actuator protein, which, when reunited, leads to cleavage of the protein resulting in the release of the transcription factor. The synthetic transcription factor, in turn, binds a specific synthetic promoter and finally activates the expression of the colorimetric reporter gene .

Our vision is a modular design , allowing for easy swap of the interleukin receptor in the yeast, so the patch can be tailored to the need of the individual patient group. The yeast is powered by designed receptors that boast very high sensitivity and selectivity, coupled with an efficient pheromone pathway for signal amplification. The patch can be photographed with a specialized app to analyze the exact level of coloration regardless of light conditions.








  1. JoAnne Epping-Jordan, Robert Beaglehole, Catherine Le Galès-Camus, et al. Preventing chronic diseases: a vital investment. 2005. WHO global report.
  2. Pahwa R, Goyal A, Bansal P, et al. Chronic Inflammation. 2020 Jul 4. Treasure Island (FL): StatPearls [Internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493173/
  3. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-1832. doi:10.1038/s41591-019-0675-0
  4. Katchman BA, Zhu M, Blain Christen J, Anderson KS. Eccrine Sweat as a Biofluid for Profiling Immune Biomarkers. Proteomics Clin Appl. 2018;12(6):e1800010. doi:10.1002/prca.201800010
  5. Marques-Deak A, Cizza G, Eskandari F, et al. Measurement of cytokines in sweat patches and plasma in healthy women: validation in a controlled study. J Immunol Methods. 2006;315(1-2):99-109. doi:10.1016/j.jim.2006.07.011
  6. Hladek MD, Szanton SL, Cho YE, et al. Using sweat to measure cytokines in older adults compared to younger adults: A pilot study. J Immunol Methods. 2018;454:1-5. doi:10.1016/j.jim.2017.11.003
  7. Vollmer P, Peters M, Ehlers M, et al. Yeast expression of the cytokine receptor domain of the soluble interleukin-6 receptor. J Immunol Methods. 1996;199(1):47-54. doi:10.1016/s0022-1759(96)00163-9

Icons made by Freepik from www.flaticon.com